Rebirth of the Strongest Tycoon

After determining the target, Xia Yu immediately took out a part of the company's elite, formed a complete acquisition team, and began to collect detailed information on the target.

Many of these elites recruited by targeted hunting have worked in capital management companies or venture capital firms in San Francisco or Silicon Valley, and they are very well informed about the venture capital field in recent years.

In just five days, Genentech's detailed information was collected and presented to Xia Yu's desk.

Genentech is just an abbreviation, and the company's full name is American Genetic Engineering Technology Corporation.

The company was founded on April 7, 1976 and is now based in San Francisco.

In later generations, Genentech can be regarded as the oldest biotechnology company in the United States, second only to Amgen in size and strength.

However, in later generations, Genentech was acquired by the Swiss Roche Pharmaceutical Group, which acquired a 60% stake in Genentech for $2.1 billion in 1990.

In 2009, the Swiss pharmaceutical group Roche once again invested about US$46.8 billion to acquire the remaining 40% stake.

In other words, by 2009, Genentech was valued at more than 111 billion US dollars.

Genentech's future is undoubtedly extremely brilliant, but now, it is just a young company that has been established for more than three years and nearly four years, and has not gone public.

Genentech was able to be established, and it has been able to develop smoothly even with losses.

In the beginning, it was 27-year-old Robert Swanson, a partner of a venture capital firm named Coller Perkins, and a biochemist at the University of California, the founder of the field of DNA recombination, in 1976. Genentech was established with Professor Herb Boyle, the Nobel Prize winner.

At that time, Robert Swanson won $100,000 in funding from the company, and Professor Herb Boyle put up $26,000 in savings. In return, Claire Perkins received a percent of Twenty-five shares.

Then in January 1977, the money ran out, and a venture capital firm called York Capital came along, invested $850,000, and took a 25 percent stake in Genentech. Kings Company joined the investment, and the equity savings remained at 25%.

Just nine months after its founding, Genentech's valuation soared from $400,000 to $3.37 million.

But at this time Genentech's product was still being tested.

In August 1977, Genentech synthesized a brain hormone, somatostatin. This major breakthrough made Genentech famous and attracted more attention from venture capital.

In May 1978, Genentech received its third venture capital investment of $950,000, and Constant Capital acquired 8.6 percent of the equity, all from Hewlett-Packard. It was taken in the name of Professor Boyle Boyle.

Because the venture capital industry has only been around for 20 years, the market is not large, and many aspects are not perfect. Venture capital companies have stronger initiative over startup companies than later generations. Therefore, the investment agreements signed by the other two venture capital companies are not the same as those of later generations. Another difference, the two venture capital firms continued to maintain their equity ratios, and the valuation of Genentech soared to $11 million.

In September last year, Genentech was reorganized and planned to go public, and it is already going through the approval process for going public.

It’s just that the goal of listing is Nasdaq, because Genentech is a low-asset, negative-profit, and high-valued company that can be listed on Nasdaq in the United States, and is a New York stock with greater influence and scale. Exchange, Genentech's current conditions are impossible to enter.

According to the data, Genentech now has four shareholders, with the shareholding ratio of Professor Herb Boyle holding 41.4%, and the shareholding ratio of Coller Perkins %. of twenty-five,

York Capital holds 25 percent and Constant Capital holds 8.6 percent.

According to the 1979 annual financial report last year, Genentech's total revenue was only US$6 million. Because of the successful cloning of growth hormone, many research results are being transferred from the research and development stage to the approval stage and are ready to be put into production, so the net profit is negative, and the company's total Assets are around $2.5 million.

But this does not prevent the capital market from having high expectations for Genentech!

So now you don't have to think about it, Genentech's valuation is going to be high!

Xia Yu doesn't care if the valuation is high or not, because no matter how high it is, it won't go anywhere.

For him, who has more than 20 billion US dollars in cash, it is completely trivial!

The findings included information on Genentech's three venture capital shareholders, in addition to information on Genentech.

Among them, Coller Perkins is the weakest company. Founded in 1972, the company manages four funds with a capital of less than 50 million US dollars.

Coller Perkins' investment vision is not very good, and the best investment return prospect so far is Genentech.

But now that Genentech has embarked on the road to listing, if you want to harvest the fruit, you have to wait at least half a year.

If Xia Yu's Polaris Capital can come up with money that exceeds their psychological expectations, I believe that Claire Perkins will not waste more than half a year waiting for an unknown.

After reading the information, Xia Yu called Peter Lynch and called the acquisition team to hold a meeting to study the specific acquisition plan.

Xia Yu swept over everyone's faces and set the tone first: "My goal is to acquire the equity of Claire Perkins, York Capital and Conston Capital, and to suspend Genentech. listing procedures.”

"The second step is to acquire as much equity in his hands as possible on the basis of completely retaining Professor Herb Boyle!"

At this moment, Genentech's most valuable is Professor Herb Boyle, who won the Nobel Prize, followed by his scientific research team and the patents for drugs that have been developed. As for other laboratories, production lines, etc. , it doesn't matter at all, money can always buy a better one!

In any company, the most valuable things are people.

This is more obvious in companies with a high proportion of scientific research, while Genentech is still in the early stage of growth, and the value of people is almost concentrated in Professor Herb Boyle.

"Chairman, according to normal procedures, Genentech will be listed on Nasdaq in September or October, and the market value of Genentech is generally between $100 million and $150 million. If We want to acquire the equity of the three venture capital firms, and under the temptation of going public, we have to invest at least $100 million, or even $150 million."

A middle-aged subordinate of the acquisition team got up and said.

Xia Yu immediately replied: "Money is not a problem. Now the company's initial capital is 100 million US dollars. I can apply for more funds. As long as there are suitable projects, a billion US dollars can be injected."

"Here I want to state that the consortium behind the company has enough strength, and in future investment and acquisitions, the issue of funding is not within the scope of consideration!"

As soon as these words came out, everyone present was in high spirits and realized that the company they joined was not as simple as it seemed on the surface.

But isn't it better?

In an instant, everyone's sense of belonging to the company greatly increased.

...

"Then the difficulty now is to persuade the three venture capital firms to give up the idea of ​​going public and sell the equity to us in advance!"

After the discussion, Peter Lynch concluded his speech.

"Chairman, now Genentech is in the process of going public, the sooner the acquisition, the better, so I suggest dividing it into three acquisition groups and doing it at the same time."

After that, everyone turned their attention to Xia Yu.

This was exactly what Xia Yu wanted. He nodded and said, "Well, let's divide it into three acquisition groups. I will be in charge of one, you will be in charge of one, and who is willing to take the initiative to stand up for the remaining one?"

"I!"

"Chairman, I am willing!"

"Chairman, I am competent!"

Immediately, several people rushed to speak.

The corners of Xia Yu's mouth were slightly raised, and after asking several people to explain their ideas, he selected the one with the best idea to be the leader of the acquisition team, and the others were assigned to three teams, and then reported the missing staff to Peter Lynch. , the rest of the deployment company comes in.

After that, several meetings were held, and a complete acquisition plan and an independent action plan were made.

On March 10, Xia Yu called everyone together in the company's conference room, and after expressing some moving ideas, he immediately announced his actions.

The three acquisition groups were dispatched at the same time, heading towards the three companies.

PS: North American foundation set sail, ask for tickets and ask for subscription!

https://

Please remember this book's first domain name: . Apex Novel Mobile Version Reading URL: